Celgene Corp. — Sponsor Intelligence | 55 EU Trials

Filter these 55 trials by condition, phase, country and more.

Open in Search →

55 Registered trials

11 Recruiting

42 Completed trials

23 Countries active

74 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 20 Phase II/III: 3 Phase II: 11 Phase I/II: 6 Phase I: 6 Phase I (Other): 9

Oversight events:

23 temporary halts 1 urgent safety measure 5 unexpected events 2 corrective measures across 11 trials

View oversight register →

100%

42 of 42 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Diffuse large B-cell lymphoma 4 Myelofibrosis 3 Marginal zone lymphoma 2 Acute myeloid leukaemia 2 Crohn's disease 2 Myelodysplastic syndrome 2 Systemic lupus erythematosus 2 Multiple sclerosis 2 Primary myelofibrosis 2 Follicular lymphoma 1 Glioblastoma 1 Non-small cell lung cancer 1

Top IMPs

DEXAMETHASONE 7 LUSPATERCEPT 7 MEZIGDOMIDE 7 DARATUMUMAB 5 AZACITIDINE 4 CARFILZOMIB 4 GOLCADOMIDE 4 IDECABTAGENE VICLEUCEL 4 BORTEZOMIB 3 CC-97540 3 IBERDOMIDE 3 LENALIDOMIDE 3

All trials

55 total

Phase 1b/2a Study to Evaluate Alnuctamab in Combination with Mezigdomide in Relapsed and/or Refractory Multiple Myeloma. Not authorised

2023-504367-16-00 Phase II 1 country ALNUCTAMAB; MEZIGDOMIDE
Study of BMS-986353, CD19-CAR T Cells, versus SoC in Participants with Active SSc (Breakfree-SSc) Pending

2025-524337-11-00 Phase III 4 countries CC-97540
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS… Recruiting

2022-500479-29-00 Phase II/III 10 countries AZACITIDINE
Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting

2025-522090-11-00 Phase I/II 4 countries ELRANATAMAB; MEZIGDOMIDE
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasti… Recruiting

2024-517745-14-00 Phase II 3 countries CC-97489
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting

2024-519152-82-00 Phase III 8 countries GOLCADOMIDE
A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting

2024-515279-37-00 Phase III 17 countries ARLOCABTAGENE AUTOLEUCEL
A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma Recruiting

2023-506003-26-00 Phase I 3 countries
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Phase III 16 countries ACETYLSALICYLIC ACID; APIXABAN; ENOXAPARIN SODIUM; IBERDOMIDE; LENALIDOMIDE; RIV…
Phase 2 Study of Luspatercept in Adults and Adolescents with Alpha (α)-thalassemia Recruiting

2022-502328-35-00 Phase II 2 countries LUSPATERCEPT
Phase 1b/2a Study to Evaluate CC-92480 (BMS-986348) in Combination with Other Treatments in Relapsed or Refractory Multiple Myeloma Recruiting

2023-509384-25-00 Phase I/II 2 countries 2-(3-(3,5-DIMETHYLTRIAZOL-4-YL)-5-((S)-OXAN-4-YL(PHENYL)METHYL)PYRIDO(3,2-B)INDO…
Phase 2a Study of Luspatercept in Pediatric Participants With Beta (β)-Thalassemia Recruiting

2022-502499-22-00 Phase II 3 countries LUSPATERCEPT
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting

2023-504201-36-00 Phase II/III 17 countries ARLOCABTAGENE AUTOLEUCEL; BMS-986515; BMS986453; CC-97540; IDECABTAGENE VICLEUCE…
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Ended

2024-517422-25-00 Phase III 12 countries BMS-986365
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Phase II 5 countries GOLCADOMIDE
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 Phase III 17 countries GOLCADOMIDE; PEGFILGRASTIM
A study to evaluate the efficacy and safety of JCAR017 in adult subjects with a type of cancer that affects B-cells, a type of white blood c… Ended

2024-510966-18-00 Phase II 6 countries LISOCABTAGENE MARALEUCEL
A Phase 3b Study of BMS-986346 in Lower-risk Myelodysplastic Syndrome Participants Ended

2023-504541-31-00 Phase III 7 countries LUSPATERCEPT
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Phase III 8 countries EPOETIN ALFA; LUSPATERCEPT
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended

2022-501346-30-00 Phase III 12 countries CYCLOPHOSPHAMIDE MONOHYDRATE; FLUDARABINE PHOSPHATE; FLUDARABINE PHOSPHATE PH. E…
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult… Ended

2022-500861-29-00 Phase III 11 countries CARFILZOMIB; MEZIGDOMIDE
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended

2023-509859-13-00 Phase III 13 countries BORTEZOMIB; DEXAMETHASONE; MEZIGDOMIDE; POMALIDOMIDE
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended

2024-510800-35-00 Phase III 16 countries DARATUMUMAB; DEXAMETHASONE; IBERDOMIDE
A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects… Ended

2023-506094-35-00 Phase I (Other) 3 countries

Showing 1–24 of 55 trials

← All sponsors A–Z